All In Biotech

Drug Trial Radar · NCT07944118

Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in Adults With Overweight or Obesity, With or Without Type 2 Diabetes

Investigation of the Effect of Fasting Duration and Temporary Withholding of Subcutaneous Administration of Zenagamtide on Retained Gastric Contents in Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 12, 2026

Primary completion

Jan 14, 2028

Study completion Feb 11, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to find out how the duration of fasting (not eating or drinking, except for water) and pausing of treatment with zenagamtide medication affect the amount of food and liquid left in the stomach of people using zenagamtide.

Conditions

  • Overweight
  • Obesity
  • Type 2 Diabetes

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors in one of the body parts: thigh, abdomen or upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal 1 day after dosing of s.c. zenagamtide once weekly (Yes/No)Time frame: 6, 8, 10, 12, 18 and 24 hours after start of fasting on visit 2 day 1 (V2D-1) and V19D2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences Clinical LA, Inc.

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.